The researchers were interested in the effect on cancer growth of a common immunotherapy targeting a molecule called PD-1 on immune ... blocking the EPO signaling pathway and anti-PD-1 pathway.

Cold” tumors are resistant to common immunotherapies. Stanford Medicine researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

Anti-PD-1 therapies, including one marketed commercially ... the combinatorial effect of simultaneously blocking the EPO signaling pathway and anti-PD-1 pathway. In those experiments, no mice ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.62%, which has investors questioning if this is right time to buy.

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...

- Findings support advancement of ZL-6201 into Investigational New Drug (IND)-enabling studies in 2025 as a potential first-in-class and best-in-class antibody-drug conjugate (ADC) treatment for ...

Anti-PD-1 therapies, including one marketed commercially ... the combinatorial effect of simultaneously blocking the EPO signaling pathway and anti-PD-1 pathway. In those experiments, no mice ...

PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the ...

Penpulimab-kcqx, as explained by the National Cancer Institute on its website, is a monoclonal antibody that is intended to target, bind to and inhibit the protein PD-1 and its downstream signaling ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...